Logo

Bio-Thera Signs a License Agreement with Pharmapark for BAT2506 (golimumab- biosimilar)

Share this

Bio-Thera Signs a License Agreement with Pharmapark for BAT2506 (golimumab- biosimilar)

Shots:

  • Bio-Thera will take care of full development- and commercial supply of BAT2506 out of the manufacturing facilities in Guangzhou- China. Additionally- the agreement will utilize Pharmapark’s local presence- sales- and marketing capabilities in Russia and other CIS countries
  • Pharmapark to get exclusive rights to distribute and market the product in Russia and other CIS countries including its filing practices. In Q4’20- Bio-Thera to begin its global P-III trial in PsA patients and will include patients from China- Russia- and many other countries  
  • Bio-Thera’s BAT2506 is a mAb while the company plans for regulatory submission with NMPA- EMA and the US FDA in 2023

Ref: Bio-Thera | Image: Pharma World

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions